Literature DB >> 31504679

Unified Staging System for Lewy Body Disorders: Clinicopathologic Correlations and Comparison to Braak Staging.

Charles H Adler1, Thomas G Beach2, Nan Zhang3, Holly A Shill4, Erika Driver-Dunckley1, John N Caviness1, Shyamal H Mehta1, Marwan N Sabbagh5, Geidy E Serrano2, Lucia I Sue2, Christine M Belden6, Jessica Powell6, Sandra A Jacobson7, Edward Zamrini6, David Shprecher6, Kathryn J Davis6, Brittany N Dugger8, Joseph G Hentz3.   

Abstract

This study was designed to correlate clinical findings with the extent of pathologic a-synuclein (aSyn) in the brain using the Unified Staging System for Lewy Body disorders (USSLB). Data from 280 cases from the Arizona Study of Aging and Neurodegenerative Disorders are presented. Each case had a complete USSLB staging and at least 1 full research clinical assessment, including subspecialty neurologist-administered movement and cognitive evaluation. Of the 280, 25.7% were cognitively normal, 8.6% had mild cognitive impairment, and 65.7% had dementia. All cases could be categorized into 1 of 5 USSLB stages (8.6% stage I-olfactory bulb only; 15.4% IIa-brainstem predominant; 13.6% IIb-limbic predominant; 31.8% III-brainstem and limbic; and 30.7% IV-neocortical) yet using the Braak staging system 70 cases (25.3%) could not be classified. Those with USSLB stages III and IV died at a younger age. Multiple measures of motor parkinsonism, cognitive impairment, hyposmia, and probable RBD were significantly correlated with increasing USSLB stage. We conclude that the USSLB is the most comprehensive staging system for all Lewy body disorders and allows for categorization and ranking of all brains with significant correlations to many motor and nonmotor clinical signs and symptoms.
© 2019 American Association of Neuropathologists, Inc. All rights reserved.

Entities:  

Keywords:  Braak staging system; Dementia with Lewy bodies; Incidental Lewy body disease; Lewy body; Parkinson disease; Unified Staging System for Lewy Body Disorders; a-Synuclein

Mesh:

Substances:

Year:  2019        PMID: 31504679      PMCID: PMC6751070          DOI: 10.1093/jnen/nlz080

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  38 in total

Review 1.  Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages).

Authors:  Heiko Braak; Kelly Del Tredici; Hansjürgen Bratzke; John Hamm-Clement; Daniele Sandmann-Keil; Udo Rüb
Journal:  J Neurol       Date:  2002-10       Impact factor: 4.849

2.  Staging of brain pathology related to sporadic Parkinson's disease.

Authors:  Heiko Braak; Kelly Del Tredici; Udo Rüb; Rob A I de Vos; Ernst N H Jansen Steur; Eva Braak
Journal:  Neurobiol Aging       Date:  2003 Mar-Apr       Impact factor: 4.673

3.  Staging of sporadic Parkinson disease-related alpha-synuclein pathology: inter- and intra-rater reliability.

Authors:  Christian M Müller; Rob A I de Vos; Claude-Alain Maurage; Dietmar R Thal; Markus Tolnay; Heiko Braak
Journal:  J Neuropathol Exp Neurol       Date:  2005-07       Impact factor: 3.685

4.  Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder.

Authors:  Ronald B Postuma; Anthony E Lang; Jessica Massicotte-Marquez; Jacques Montplaisir
Journal:  Neurology       Date:  2006-03-28       Impact factor: 9.910

5.  Progression and staging of Lewy pathology in brains from patients with dementia with Lewy bodies.

Authors:  Wami Marui; Eizo Iseki; Toshiki Nakai; Satoshi Miura; Masanori Kato; Kenji Uéda; Kenji Kosaka
Journal:  J Neurol Sci       Date:  2002-03-30       Impact factor: 3.181

Review 6.  Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered.

Authors:  Heiko Braak; Jürgen R Bohl; Christian M Müller; Udo Rüb; Rob A I de Vos; Kelly Del Tredici
Journal:  Mov Disord       Date:  2006-12       Impact factor: 10.338

7.  Lewy body-related alpha-synucleinopathy in aging.

Authors:  Yuko Saito; Nyoka N Ruberu; Motoji Sawabe; Tomio Arai; Hirohito Kazama; Takayuki Hosoi; Hiroshi Yamanouchi; Shigeo Murayama
Journal:  J Neuropathol Exp Neurol       Date:  2004-07       Impact factor: 3.685

8.  Defining mild cognitive impairment in Parkinson's disease.

Authors:  John N Caviness; Erika Driver-Dunckley; Donald J Connor; Marwan N Sabbagh; Joseph G Hentz; Brie Noble; Virgilio Gerald H Evidente; Holly A Shill; Charles H Adler
Journal:  Mov Disord       Date:  2007-07-15       Impact factor: 10.338

9.  The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: a critical analysis of alpha-synuclein staging.

Authors:  M E Kalaitzakis; M B Graeber; S M Gentleman; R K B Pearce
Journal:  Neuropathol Appl Neurobiol       Date:  2007-12-05       Impact factor: 8.090

Review 10.  Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.

Authors:  I G McKeith; D W Dickson; J Lowe; M Emre; J T O'Brien; H Feldman; J Cummings; J E Duda; C Lippa; E K Perry; D Aarsland; H Arai; C G Ballard; B Boeve; D J Burn; D Costa; T Del Ser; B Dubois; D Galasko; S Gauthier; C G Goetz; E Gomez-Tortosa; G Halliday; L A Hansen; J Hardy; T Iwatsubo; R N Kalaria; D Kaufer; R A Kenny; A Korczyn; K Kosaka; V M Y Lee; A Lees; I Litvan; E Londos; O L Lopez; S Minoshima; Y Mizuno; J A Molina; E B Mukaetova-Ladinska; F Pasquier; R H Perry; J B Schulz; J Q Trojanowski; M Yamada
Journal:  Neurology       Date:  2005-10-19       Impact factor: 9.910

View more
  8 in total

Review 1.  Depression in Patients with Parkinson's Disease: Current Understanding of its Neurobiology and Implications for Treatment.

Authors:  Stéphane Prange; Hélène Klinger; Chloé Laurencin; Teodor Danaila; Stéphane Thobois
Journal:  Drugs Aging       Date:  2022-06-16       Impact factor: 4.271

2.  Blinded RT-QuIC Analysis of α-Synuclein Biomarker in Skin Tissue From Parkinson's Disease Patients.

Authors:  Sireesha Manne; Naveen Kondru; Huajun Jin; Geidy E Serrano; Vellareddy Anantharam; Arthi Kanthasamy; Charles H Adler; Thomas G Beach; Anumantha G Kanthasamy
Journal:  Mov Disord       Date:  2020-09-22       Impact factor: 10.338

Review 3.  Prodromal Parkinson disease subtypes - key to understanding heterogeneity.

Authors:  Daniela Berg; Per Borghammer; Seyed-Mohammad Fereshtehnejad; Sebastian Heinzel; Jacob Horsager; Eva Schaeffer; Ronald B Postuma
Journal:  Nat Rev Neurol       Date:  2021-04-20       Impact factor: 42.937

Review 4.  Towards an improved early diagnosis of neurodegenerative diseases: the emerging role of in vitro conversion assays for protein amyloids.

Authors:  Niccolò Candelise; Simone Baiardi; Alessia Franceschini; Marcello Rossi; Piero Parchi
Journal:  Acta Neuropathol Commun       Date:  2020-07-25       Impact factor: 7.801

5.  Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study.

Authors:  Johannes Attems; Jon B Toledo; Lauren Walker; Ellen Gelpi; Steve Gentleman; Glenda Halliday; Tibor Hortobagyi; Kurt Jellinger; Gabor G Kovacs; Edward B Lee; Seth Love; Kirsty E McAleese; Peter T Nelson; Manuela Neumann; Laura Parkkinen; Tuomo Polvikoski; Beata Sikorska; Colin Smith; Lea Tenenholz Grinberg; Dietmar R Thal; John Q Trojanowski; Ian G McKeith
Journal:  Acta Neuropathol       Date:  2021-01-05       Impact factor: 17.088

Review 6.  Lewy body disease or diseases with Lewy bodies?

Authors:  Kateřina Menšíková; Radoslav Matěj; Carlo Colosimo; Raymond Rosales; Lucie Tučková; Jiří Ehrmann; Dominik Hraboš; Kristýna Kolaříková; Radek Vodička; Radek Vrtěl; Martin Procházka; Martin Nevrlý; Michaela Kaiserová; Sandra Kurčová; Pavel Otruba; Petr Kaňovský
Journal:  NPJ Parkinsons Dis       Date:  2022-01-10

7.  Differentially targeted seeding reveals unique pathological alpha-synuclein propagation patterns.

Authors:  Shady Rahayel; Bratislav Mišić; Ying-Qiu Zheng; Zhen-Qi Liu; Alaa Abdelgawad; Nooshin Abbasi; Anna Caputo; Bin Zhang; Angela Lo; Victoria Kehm; Michael Kozak; Han Soo Yoo; Alain Dagher; Kelvin C Luk
Journal:  Brain       Date:  2022-06-03       Impact factor: 15.255

8.  A glutaminyl cyclase-catalyzed α-synuclein modification identified in human synucleinopathies.

Authors:  Maike Hartlage-Rübsamen; Alexandra Bluhm; Sandra Moceri; Lisa Machner; Janett Köppen; Mathias Schenk; Isabel Hilbrich; Max Holzer; Martin Weidenfeller; Franziska Richter; Roland Coras; Geidy E Serrano; Thomas G Beach; Stephan Schilling; Stephan von Hörsten; Wei Xiang; Anja Schulze; Steffen Roßner
Journal:  Acta Neuropathol       Date:  2021-07-26       Impact factor: 17.088

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.